Clinical TrialsThe independent Data Monitoring Committee recommended the sunRIZE study continue as planned with no increase in sample size, indicating confidence in the current study results.
Financial StabilityRezolute has $88M in cash and raised $97M net in April, indicating strong financial stability.
Market OpportunityCHI is a small but significant market opportunity, and label expansion into tumor HI could nearly double the market.